Detail akcie FibroBiologics Rg online

Business Summary: FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Fibrobiologics Inc revenues was not reported. Net loss increased 91% to $15.4M. Higher net loss reflects Biotechnology & Medical Research segment loss increase of 40% to $14.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.26 to -$0.39.